Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients
  • Policy / Pricing

Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients

BioSpace

With a greenlight for ibogaine to enter clinical testing and three unnamed products set to receive Commissioner's National Priority Vouchers this week, it's full speed ahead for psychedelics.

Policy / PricingNeuroscienceRead full story

pharminent April 22, 2026 (Last updated: April 22, 2026)

BioSpace

With a greenlight for ibogaine to enter clinical testing and three unnamed products set to receive Commissioner’s National Priority Vouchers this week, it’s full speed ahead for psychedelics.

Policy / PricingNeuroscienceRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Neurology, biomanufacturing start-ups bag UK AI funding
Next: Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial

Related Stories

  • Policy / Pricing

Eli Lilly issues data sharing ultimatum to 340B hospitals

pharminent June 2, 2026
  • Policy / Pricing

SCOTUS won’t hear pharma’s IRA complaints

pharminent May 19, 2026
  • Policy / Pricing

Hospital Prices Have Risen Much Faster for Private Insurance Than Medicare Since 2019

pharminent May 18, 2026

You May Have Missed

  • Policy / Pricing

Eli Lilly issues data sharing ultimatum to 340B hospitals

pharminent June 2, 2026
  • M&A / Deals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

pharminent June 2, 2026
  • Clinical Data

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

pharminent June 2, 2026
  • Clinical Data

ASCO26: In vivo oncology approaches continue to show promise

pharminent June 2, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.